经皮穿刺微波凝固联合替吉奥治疗结肠癌肝转移的疗效观察  

Combined Percutaneous Microwave Coagulation Therapy and S-1 in Treatment of Liver Metastases from Colon Cancer

作　　者：许涛 张涛[1] 高辉[1] 周进军[1] 苏晓妹[1] 谭勇[1] 郑颖[1] 

机构地区：[1]成都军区总医院肿瘤诊治中心,成都610083

出　　处：《肿瘤防治研究》2012年第11期1376-1378,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察经皮穿刺微波凝固治疗(PMCT)术后联合替吉奥胶囊(S-1)治疗结肠癌肝转移的疗效。方法选择本中心2009年5月—2011年1月收治的56例结肠癌肝转移患者,分为PMCT术后联合替吉奥组(实验组,n=28)和单用PMCT组(对照组,n=28)。实验组PMCT术后口服替吉奥胶囊每日50 mg/m2,连续给药14天,停药7天,共化疗6个疗程。结果实验组和对照组治疗结束时完全缓解率分别为67.85%(19/28)和35.71%(10/28),部分缓解率分别为25%(7/28)和21.42%(6/28),稳定率分别为3.5%(1/28)和28.57%(8/28),有效率分别为92.85%(26/28)和57.14%(16/28),两组相比差异均有统计学意义(P<0.05)。不良反应主要为骨髓抑制、胃肠道反应等。结论结肠癌肝转移患者PMCT术后联合替吉奥化疗可提高患者术后生存率且不良反应较轻,是结肠癌根治术后伴肝转移有益的辅助治疗方案。Objective To evaluate the effect of percutaneous microwave coagulation therapy（PMCT） combined with S-1 in the treatment of liver metastases from colon cancer.Methods From May 2009 to January 2011,56 patients with liver metastases from colon cancer were randomly divided into treatment group（PMCT and S-1） and control group（only PMCT）.In the treatment group,S-1 was administered 50 mg/m2/d for 14 consecutive days following a 1-week rest,3 weeks for a cycle.The effects were evaluated after 6 cycles.Results There were 19（67.85%） CR,7（25%） PR,1（3.5%） SD in the treatment group,and 10（35.71%） CR,6（21.42%） PR,8（28.57%） SD in the control group.The overall response rates were 92.85% and 57.14%,respectively.There was significant difference between two groups（P0.05）.Major adverse reactions were myelosuppressive and gastrointestinal toxicities.Conclusion PMCT combined with S-1 shows well tolerance and good effect as a new therapy for patients with liver metastases from colon cancer.

关 键 词：结肠癌 经皮穿刺微波凝固治疗 替吉奥胶囊 

分 类 号：R735.35[医药卫生—肿瘤] R730.58[医药卫生—临床医学]